Kathy Harpst, Stephanie Hartfield, Fredia Rice, Jo'Quita Sanders, Shannon Malm and Lagean Medearis v. George Fleming and Fleming & Associates, L.L.P.

566 S.W.3d 898
CourtCourt of Appeals of Texas
DecidedDecember 21, 2018
Docket14-17-00209-CV
StatusPublished
Cited by14 cases

This text of 566 S.W.3d 898 (Kathy Harpst, Stephanie Hartfield, Fredia Rice, Jo'Quita Sanders, Shannon Malm and Lagean Medearis v. George Fleming and Fleming & Associates, L.L.P.) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kathy Harpst, Stephanie Hartfield, Fredia Rice, Jo'Quita Sanders, Shannon Malm and Lagean Medearis v. George Fleming and Fleming & Associates, L.L.P., 566 S.W.3d 898 (Tex. Ct. App. 2018).

Opinion

Affirmed and Opinion filed December 21, 2018.

In The

Fourteenth Court of Appeals

NO. 14-17-00209-CV

KATHY HARPST, STEPHANIE HARTFIELD, FREDIA RICE, JO’QUITA SANDERS, SHANNON MALM, AND LAGEAN MEDEARIS, Appellants V.

GEORGE FLEMING AND FLEMING & ASSOCIATES, L.L.P., Appellees

On Appeal from the 189th District Court Harris County, Texas Trial Court Cause No. 2010-25097-A

OPINION After a law firm settled tort claims against a drug manufacturer on behalf of approximately 8,000 clients, about half the settling clients sued the firm and one of the firm’s lawyers. The clients did not seek to set aside the settlement, but asserted breach of fiduciary duty and contract claims based on their attorneys’ alleged failure to disclose certain information related to the settlement and the deduction of allegedly unreasonable expenses from the clients’ recovery. The trial court severed six clients’ claims, which proceeded to trial. A jury returned a verdict in the defendants’ favor on two dispositive questions, finding that the defendants complied with their fiduciary duty and did not breach the clients’ fee agreements by charging unreasonable expenses. The trial judge signed a take-nothing judgment consistent with the jury’s verdict, and the clients now appeal.

Appellants challenge the judgment in five issues. First, they argue that the trial court erroneously dismissed one of their claims by granting a pre-trial sua sponte summary judgment in the defendants’ favor. On review of the record, we conclude that the complained-of ruling was a limine ruling, which preserves nothing for our review. Second, appellants argue that the trial court erroneously excluded evidence that they were falsely promised free echocardiograms by law firms that referred them to the defendants. According to appellants, the defendants bear responsibility for the referring firms’ false promises because the firms entered into joint ventures to recruit appellants as clients. Because we conclude that the trial plaintiffs did not plead this theory of vicarious responsibility, we hold that the trial court did not abuse its discretion in excluding the evidence. Third, appellants argue that the trial court erroneously excluded a witness from testifying. However, appellants have not challenged all possible grounds that support the trial court’s ruling, and thus they present nothing for our review. Fourth, appellants argue that the trial court erroneously precluded them from presenting evidence on and submitting to the jury an additional breach of contract theory. We conclude that the trial court’s error, if any, was harmless on this record. Finally, appellants argue that the trial court abused its discretion by refusing appellants certain discovery unless they paid the defendants’ attorney’s fees. Because the record contains no such discovery order, we cannot and do no reach the merits of appellants’ final issue. We affirm the trial court’s judgment.

2 Background

In the mid-1990s, users of the prescription diet drug combination fenfluramine/phentermine, commonly known as “fen-phen,” began to experience heart problems. The drug maker, then known as American Home Products and now known as Wyeth, removed fen-phen from the market in 1997. Across the country, thousands of fen-phen users filed legal actions against the drug maker.

A federal multidistrict litigation (MDL) court was designated to handle pretrial matters in fen-phen cases.1 The MDL court eventually certified a nationwide class action but also set forth certain procedures and requirements for individual suits. Any claimant preferring to opt out of the nationwide class action and pursue an individual claim had to establish his or her eligibility to sue by undergoing an echocardiogram2 resulting in a “FDA-positive” reading. Actions by individuals who did not meet the “FDA-positive” threshold were subject to dismissal.

A Houston lawyer, George Fleming, and his then-law firm, Fleming & Associates, L.L.P. (collectively referred to as “the Fleming Firm”), established a nationwide echocardiogram program—at an alleged cost of at least $20 million—to screen potential claimants for eligibility to opt out of the class and assert individual claims. According to the Fleming Firm, more than 40,000 potential clients were screened, and the firm eventually represented over 8,000 “FDA-positive” claimants in pursuing individual claims for personal injuries against Wyeth.

In 2006, Wyeth and the Fleming Firm’s 8,051 clients agreed to settle the claims for an aggregate amount of $339 million. Wyeth and the Fleming Firm signed a master settlement agreement (“MSA”), pursuant to which Wyeth would escrow

1 See generally In re Diet Drugs, 385 F.3d 386, 389-90 (3d Cir. 2004). 2 An echocardiogram is “a graphic outline of the movements of heart structures produced by ultrasonography.” Mosby’s Medical Dictionary 581 (9th ed. 2013).

3 the settlement amount and the firm would disburse the settlement amount to each claimant. Under the MSA terms, the Fleming Firm agreed to, inter alia: (a) comply with applicable rules of legal ethics “in connection with this Settlement Agreement and the matters contemplated herein”; (b) advise the clients that they would have no further recourse against Wyeth as a result of the Fleming Firm’s allocation and distribution of the settlement amount once each claimant signed a release; and (c) allocate and distribute the settlement amount to the claimants and other attorneys who had a financial interest in the settled claims “in accordance with any retainer agreements or other contractual agreements between them.”

Each of the firm’s clients then received a twenty-five-page “settlement packet,” which explained the nature of the settlement, included a statement showing that particular client’s individual net settlement amount after deductions for attorney’s fees and client expenses, and answered “commonly asked questions” about the aggregate settlement. Each settlement packet also included a spreadsheet showing the amount of settlement funds allocated to each of the Fleming Firm’s clients. More than 95% of the Fleming Firm’s clients accepted the settlement and signed releases.3

A few years later, a number of the Fleming Firm’s former clients who had accepted the settlement and signed releases sued the firm and George Fleming individually for, as relevant here, breach of contract and breach of fiduciary duty. 4 The clients alleged that the Fleming Firm breached its contractual and fiduciary duties in several respects. First, the clients asserted that the firm wrongfully

3 Wyeth’s MSA obligations were contingent upon, inter alia, 95% of the firm’s clients accepting the settlement and executing releases. 4 The clients asserted a number of other causes of action, as discussed in the opinion for the related Wilson appeal also issued today, Wilson v. Fleming, No. 14-17-00223-CV, ---S.W.3d--- (Tex. App.—Houston [14th Dist.] Dec. 21, 2018, no pet. h.).

4 deducted from their settlement payout a pro rata share of expenses for the echocardiogram program, including the screening costs for people whose echocardiograms did not meet the MDL court’s opt-out criteria. In other words, the clients alleged that they had to pay a portion of the echocardiogram costs of everyone who was tested, including those potential claimants who failed the FDA screening criteria and never asserted individual claims against Wyeth. Although each of the clients’ fee agreements provided that the firm could recover “reasonable” expenses of litigation, the clients contended that the echocardiogram program’s overall cost was not an allowable, reasonable expense. Second, the clients claimed they were charged for their own echocardiograms, despite promises that those tests would be free to them.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Marcus Jacquot v. Melody Coker
Court of Appeals of Texas, 2021
Anitra M. Carter v. Shaun Gormley
Court of Appeals of Texas, 2021

Cite This Page — Counsel Stack

Bluebook (online)
566 S.W.3d 898, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kathy-harpst-stephanie-hartfield-fredia-rice-joquita-sanders-shannon-texapp-2018.